PMID- 24944352
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140619
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 64
IP  - 1
DP  - 2003 Jan
TI  - Treatment and treatment-related adverse events of type 2 diabetes mellitus in 
      residents of long-term care facilities: a retrospective study.
PG  - 1-9
LID - 10.1016/S0011-393X(03)00005-5 [doi]
AB  - BACKGROUND: In the United States, type 2 diabetes mellitus (DM) is most prevalent 
      among adults aged >75 years. Judicious use of available therapies can improve 
      plasma glucose concentration and reduce the risk for complications in elderly 
      patients. However, selecting the appropriate medication for these patients is 
      often challenging. OBJECTIVES: The goals of this retrospective study were to 
      determine whether 1 or 2 medications were needed for the treatment of type 2 DM 
      in elderly patients and to identify treatment-related adverse events (AEs). 
      METHODS: The charts of residents of long-term care (LTC) facilities in New Jersey 
      and Pennsylvania with a diagnosis of type 2 DM and receiving metformin, a 
      sulfonylurea, rosiglitazone, or pioglitazone, either alone or in combination with 
      insulin or another drug, were included. Data for laboratory values (including 
      fasting plasma glucose [FPG] and serum creatinine concentration), body weight, 
      and AEs were analyzed. RESULTS: The charts of 182 patients (121 women, 61 men) 
      were included. The mean (SD) age of the women was 80.2 (10.2) years; and of the 
      men, 73.7 (12.0) years. Many patients were switched from monotherapy to 
      combination therapy due to a high FPG concentration. Sixty treatment-related AEs 
      occurred in 60 patients; the pioglitazone and metformin groups had the highest 
      incidence of AEs (8/11 [72.7%] patients and 21/48 [43.8%] patients, respectively) 
      and the rosiglitazone group had the lowest (2/13 [15.4%] patients), although the 
      number of patients in the pioglitazone and rosiglitazone groups was extremely 
      low. CONCLUSIONS: In this study population of older patients, rosiglitazone 
      monotherapy had favorable tolerability and appeared to be more effective than 
      other therapies for type 2 DM. These results suggest that rosiglitazone 
      monotherapy may be the safest and most effective of the 4 treatments for type 2 
      DM in older patients. The rosiglitazone group was the only group that did not 
      have a second medication added to control plasma glucose. However, additional 
      studies are suggested to determine whether larger groups of older patients 
      residing in LTC facilities would demonstrate similar results.
FAU - Frenchman, I Barton
AU  - Frenchman IB
AD  - Pharm Rx Consultants, Inc., Union, New Jersey, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC4053022
OTO - NOTNLM
OT  - metformin
OT  - pioglitazone
OT  - rosiglitazone
OT  - sulfonylurea
OT  - type 2 diabetes mellitus
EDAT- 2003/01/01 00:00
MHDA- 2003/01/01 00:01
PMCR- 2003/01/01
CRDT- 2014/06/20 06:00
PHST- 2002/10/16 00:00 [accepted]
PHST- 2014/06/20 06:00 [entrez]
PHST- 2003/01/01 00:00 [pubmed]
PHST- 2003/01/01 00:01 [medline]
PHST- 2003/01/01 00:00 [pmc-release]
AID - S0011-393X(03)00005-5 [pii]
AID - 10.1016/S0011-393X(03)00005-5 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2003 Jan;64(1):1-9. doi: 10.1016/S0011-393X(03)00005-5.